Kerscher M J, Korting H C
Dermatologische Klinik und Poliklinik Ludwig-Maximilians Universität München.
Clin Investig. 1992 Feb;70(2):167-71. doi: 10.1007/BF00227362.
Recently a defect in the function of the enzyme delta-6-desaturase has been discussed as a major factor in the development of atopic eczema. Delta-6-desaturase is responsible for the conversion of linoleic acid to gamma linolenic acid. Several plants, including evening primrose, are known to be fairly rich in gamma linolenic acid. Hence, substitution of gamma linolenic acid in patients prone to developing atopic eczema seems like a feasible concept. During the last few years different clinical trials have been performed. Controlled trials following a parallel study design showed marked improvement in atopic eczema. Patients treated with the drug showed less inflammation, dryness, scaling and overall severity compared to controls. Although these findings have been supported by meta-analysis, there is still conflicting evidence in trials based on a crossover design alone, demonstrating a decrease in itching. At present, evening primrose oil in doses used for the treatment of atopic eczema is considered safe. However, still more trials addressing both efficacy and safety are needed to make a final decision.
最近，有人讨论了δ-6-去饱和酶功能缺陷是特应性皮炎发病的一个主要因素。δ-6-去饱和酶负责将亚油酸转化为γ-亚麻酸。包括月见草在内的几种植物，已知富含γ-亚麻酸。因此，对于易患特应性皮炎的患者，用γ-亚麻酸替代似乎是一个可行的概念。在过去几年中，已经进行了不同的临床试验。采用平行研究设计的对照试验显示，特应性皮炎有显著改善。与对照组相比，接受该药物治疗的患者炎症、干燥、脱屑及总体严重程度均较轻。尽管这些发现得到了荟萃分析的支持，但仅基于交叉设计的试验仍有相互矛盾的证据，表明瘙痒有所减轻。目前，用于治疗特应性皮炎的月见草油剂量被认为是安全的。然而，仍需要更多针对疗效和安全性的试验才能做出最终决定。
